Insider filing · MANE

John W Childs bought $5.0M of Veradermics (MANE)

Executed Feb 5, disclosed Feb 6, the same day.

Over the 21 trading sessions from the disclosed entry session (Feb 5), the stock returned +27.0% (delay-adjusted); from the execution session (Feb 5), +27.0%. Derived: entry at the session's open, exit at the close 20 sessions later.

JC John W Childs Director profile →

John W Childs (Director) filed 5 Form 4 reports in the trailing twelve months (4 purchases, 1 sale, 2 filed past the two-business-day deadline), most often in BHVN. Across 2 priced purchase filings, the average 21-session return was +37.0% from execution and +27.3% from disclosure (delay-adjusted; derived). The largest single filing was $25.0M of BHVN (3,333,333 sh × $7.50, as filed), executed Nov 13 2025.

MANE Veradermics, Incorporated MANE · Healthcare · 10 filings in 24 months ticker →

Healthcare · Veradermics, Incorporated, a clinical-stage biopharmaceutical company, focused on developing novel therapeutics for dermatologic and aesthe…

More Healthcare filings→ Insider filings, newest first→ View the original filing at www.sec.gov→